Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics
Abstract
Mantle cell lymphoma (MCL) is a well-defined lymphoid malignancy characterized by a rapid clinical evolution and poor response to current therapeutic protocols. The genetic and molecular mechanisms involved in its pathogenesis combine the dysregulation of cell proliferation and survival pathways with a high level of chromosome instability that seems related to the disruption of the DNA damage response pathway. Understanding these mechanisms and how they affect tumour behaviour is providing the rationale for the identification of reliable predictors of clinical evolution and the design of innovative therapeutic strategies that could open new avenues for the treatment of patients with MCL.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MCL is an incurable B cell non-Hodgkin lymphoma whose molecular hallmark is the t(11;14)(q13;q32) chromosomal translocation that juxtaposes CCND1 with the Ig heavy chain gene locus, resulting in aberrant cell cycle progression via activation of CDK4/6.
“CDK4/6 inhibitors are currently being evaluated for MCL, an incurable B cell non-Hodgkin lymphoma whose molecular hallmark is the t(11;14)(q13;q32) chromosomal translocation that juxtaposes CCND1 (encoding cyclin D1) with the Ig heavy chain gene locus, resulting in aberrant cell cycle progression via activation of CDK4/6[17].”
From Development of dual and selective degraders of cyclin-dependent kinases 4 and 6 (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213 · see citing works
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Gallinari, P., Marco, S. D., Jones, P., Pallaoro, M., & Steinkühler, C. (2007) · Cell Research · doi:10.1038/sj.cr.7310149 · Cited by 678 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370 · see citing works
Nuclear cyclin D1: an oncogenic driver in human cancer
Kim, J. K., & Diehl, J. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21791 · Cited by 413 · see citing works
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299 · see citing works
Development of dual and selective degraders of cyclin-dependent kinases 4 and 6
Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901336 · Cited by 272 · see citing works
Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204 · see citing works
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Williamson, C. T., Muzik, H., Turhan, A. G., Zamò, A., O'Connor, M. J., Bebb, D. G., & Lees-Miller, S. P. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0872 · Cited by 193 · see citing works
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
Ma, J., Lu, P., Guo, A., Cheng, S., Zong, H., Martin, P., Coleman, M., & Wang, Y. L. (2014) · British Journal of Haematology · doi:10.1111/bjh.12974 · Cited by 90 · see citing works
Tabe, Y., Sebasigari, D., Jin, L., Rudelius, M., Davies-Hill, T., Miyake, K., Miida, T., Pittaluga, S., & Raffeld, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0399 · Cited by 83 · see citing works
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
Jacobson, C., Kopp, N., Layer, J. V., Redd, R. A., Tschuri, S., Haebe, S., van Bodegom, D., Bird, L., Christie, A. L., Christodoulou, A., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711176 · Cited by 45 · see citing works
- Authors
- Jares, P., Colomer, D., & Campo, E.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Venue
- Nature Reviews Cancer
- Published
- 2007-10
- Volume
- 7
- Issue
- 10
- Pages
- 750-762
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2020619763
- Cited by
- 466
- References
- 2
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 9 · 2023: 14 · 2022: 13 · 2021: 15 · 2020: 18 · 2019: 20 · 2018: 25 · 2017: 19 · 2016: 26 · 2015: 27 · 2014: 32 · 2013: 41 · 2012: 41
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Lymphoma Research Foundation
- Leukemia Research Foundation
- Leukemia and Lymphoma Research
- European Commission
- Comisión Interministerial de Ciencia y Tecnología
- Julius-Maximilians-Universität Würzburg
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- mantle cell lymphoma, pathogenesis, molecular pathogenesis, chromosomal instability, DNA damage response, B cell proliferation, cell survival pathways, prognostic factors, targeted therapy, tumor evolution
- MeSH terms
- Antineoplastic Agents, B-Lymphocytes, Cell Cycle, Cell Differentiation, Cell Survival, DNA Damage, Drug Evaluation, Humans, Proto-Oncogenes, Translocation, Genetic, Gene Expression, Cyclins, Drug Delivery Systems, Apoptosis, Cyclin D1, Lymphoma, Mantle-Cell, Cyclin D, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
